Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Ibiayi Dagogo-Jack"'
Autor:
Laura Spring, Barbara L. Smith, Jochen K. Lennerz, Veerle Bossuyt, Ibiayi Dagogo-Jack, Leif W. Ellisen, Loren Winters, Lesli A. Kiedrowski, Alphonse G. Taghian, Zehra Ordulu, Aditya Bardia, Lindsey Mortensen
Publikováno v:
Oncologist
Enhanced understanding of the molecular events underlying oncogenesis has led to the development of “tumor‐agnostic” treatment strategies, which aim to target a tumor's genomic profile regardless of its anatomic site of origin. A classic exampl
Autor:
Alice T. Shaw, Jochen K. Lennerz, Rebecca S. Heist, Justin F. Gainor, Kelly Goodwin, Andrew Do, Philicia Moonsamy, Ibiayi Dagogo-Jack, Aaron N. Hata, Subba R. Digumarthy, Inga T. Lennes, Zofia Piotrowska, Kristin Price, Sara Stevens, Alona Muzikansky, Jessica J. Lin, Lecia V. Sequist
Publikováno v:
Journal of Thoracic Oncology. 16:850-859
Introduction Capmatinib is approved for MET exon 14–altered NSCLC on the basis of activity in targeted therapy–naive patients. We conducted a phase 2 study to assess the efficacy of capmatinib in patients previously treated with a MET inhibitor.
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Jean M. Connors, Ibiayi Dagogo-Jack, Orly Leiva, Alice T. Shaw, Anthony J. Iafrate, Jochen K. Lennerz, Hanny Al-Samkari, Pavan K. Bendapudi
Publikováno v:
Journal of Thoracic Oncology. 15:1497-1506
Clinical venous thromboembolism (VTE) risk prediction scores, such as the Khorana Risk Score, perform poorly in NSCLC, possibly because the tumor molecular subtype is omitted. Previous studies suggest a possible increased VTE risk in ALK-rearranged N
Autor:
Kylie Prutisto Chang, Mari Mino-Kenudson, Alice T. Shaw, Adam Langenbucher, Michael S. Lawrence, Marina Kem, Pranav Gupta, Justin F. Gainor, Isobel J Fetter, Andrew Do, Satoshi Yoda, Jessica J. Lin, Ibiayi Dagogo-Jack, Audris Oh, Marguerite Rooney, Aaron N. Hata, James R. Stone, Ryan B. Corcoran, Emily Chin, Jochen K. Lennerz, Dejan Juric
Publikováno v:
npj Precision Oncology, Vol 4, Iss 1, Pp 1-8 (2020)
NPJ Precision Oncology
NPJ Precision Oncology
Histologic transformation from non-small cell to small cell lung cancer has been reported as a resistance mechanism to targeted therapy in EGFR-mutant and ALK fusion-positive lung cancers. Whether small cell transformation occurs in other oncogene-dr
Autor:
Subba R. Digumarthy, Ibiayi Dagogo-Jack, Mannudeep K. Kalra, Ramandeep Singh, Eric W. Zhang, Dexter P. Mendoza, Atul Padole
Publikováno v:
Translational Lung Cancer Research. 9:1441-1451
Background The clinical features and traditional semantic imaging characteristics of BRAF-mutated non-small cell lung cancer (NSCLC) have been previously reported. The radiomic features of BRAF-mutated NSCLC and their role in predicting cancer stage,
Autor:
Emily Chin, Cyril H. Benes, Sara Stevens, Subba R. Digumarthy, Ashish Saxena, Alice T. Shaw, Beow Y. Yeap, Rebecca J. Nagy, Christopher G. Azzoli, Hetal D. Marble, Jessica J. Lin, Justin F. Gainor, Adam Langenbucher, Kylie Prutisto-Chang, Andrew Do, Jochen K. Lennerz, Satoshi Yoda, Nathaniel A. Adams, Marguerite Rooney, Aaron N. Hata, Michael S. Lawrence, Audris Oh, Ibiayi Dagogo-Jack
Publikováno v:
Clin Cancer Res
Purpose: Most ALK-positive lung cancers will develop ALK-independent resistance after treatment with next-generation ALK inhibitors. MET amplification has been described in patients progressing on ALK inhibitors, but frequency of this event has not b
Autor:
Ibiayi Dagogo-Jack, Alice T. Shaw, Alexa B. Schrock, Siraj M. Ali, Nicholas A. Jessop, Marina Kem, Mari Mino-Kenudson, J. Lee, Jeffrey S. Ross, Jochen K. Lennerz
Publikováno v:
Journal of Thoracic Oncology. 15:766-776
Introduction Ten percent of NSCLCs harbor mutations in SMARCA4, the gene encoding the SWItch/Sucrose Non-Fermentable ATPase BRG1. In preclinical models, BRG1 inactivation increases tumor aggressiveness but enhances sensitivity to drugs that target ox
Autor:
Scott L. Carter, Juan Carlos Martinez-Gutierrez, Tracy T. Batchelor, Ibiayi Dagogo-Jack, Christopher Alvarez-Breckenridge, Priscilla K. Brastianos, Sun Ha Paek, Michael White, Benjamin Kaufman, Kaitlin Hoang, Nicholas D. Camarda, Daniel P. Cahill, Megan R. D'Andrea, Anna S. Berghoff, Mia Bertalan, Parker H. Merrill, Darrell R. Borger, Sun Hye Park, Devin McCabe, Sandro Santagata, Deepika Nagabhushan, Franziska M. Ippen, A. John Iafrate, Matthew R. Strickland, Ryan P. Frazier, Naema Nayyar, Matthew Lastrapes, Ivanna Bihun, Emily Batchelor, Elisa Aquilanti, Maria Martinez-Lage, Brandyn A. Castro, Ben Kuter, Matthias Preusser, Matthew P. Frosch, Magali De Sauvage, David Shih, Andrew Kaneb, Bruce E. Johnson, Alexander Kaplan, Ugonma Chukwueke, Elizabeth R. Gerstner, Corey M. Gill
Publikováno v:
Nature Genetics. 52:371-377
Brain metastases from lung adenocarcinoma (BM-LUAD) frequently cause patient mortality. To identify genomic alterations that promote brain metastases, we performed whole-exome sequencing of 73 BM-LUAD cases. Using case-control analyses, we discovered
Autor:
Beow Y. Yeap, Jochen K. Lennerz, Harper Hubbeling, Rebecca J. Nagy, Jennifer Ackil, Jessica J. Lin, Marguerite Rooney, Aaron N. Hata, Emily Chin, Anna F. Farago, Alice T. Shaw, Justin F. Gainor, Richard B. Lanman, Ibiayi Dagogo-Jack
Publikováno v:
Clinical Cancer Research. 25:6662-6670
Purpose: Acquired resistance to next-generation ALK tyrosine kinase inhibitors (TKIs) is often driven by secondary ALK mutations. Here, we investigated utility of plasma genotyping for identifying ALK resistance mutations at relapse on next-generatio